Short answer
ResMed (RMD) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 covers ResMed’s quarter and fiscal year ended June 30, 2026.
ResMed 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Exhibit 99.1 covers ResMed’s quarter and fiscal year ended June 30, 2026
- Earnings information is furnished under Item 2.02 for investor review
- Results press release issued August 6, 2026
Item 8.01 · Other Events
- Quarterly dividend increased 10% to $0.66 per share, signaling continued shareholder-return capacity
- Record date August 20, 2026; payment scheduled for September 24, 2026
- Ex-dividend date August 19, 2026 for NYSE shares and ASX-traded CDIs
- CDI holders receive Australian-currency equivalent based on record-date exchange rate and 10:1 CDI-to-share ratio
- ASX conversion processing deferred August 19–20, 2026 under granted settlement-rule waiver
Item EX-99.1 · Exhibit EX-99.1
- FY2026 revenue rose 10% to $5.7B, with non-GAAP EPS up 17% to $11.17
- FY2026 non-GAAP operating margin expanded 180 bps to 36.1%, indicating strong productivity execution
- $1.6B free cash flow supported more than $1B returned to shareholders during FY2026
- FY2027 shareholder-return target exceeds $1.85B, with quarterly dividend increased 10% to $0.66
- MatrixCare sale and Noctrix Health acquisition reshape the portfolio entering fiscal 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ResMed 8-K filings
Get the next RMD 8-K as it lands
Follow RMD for push alerts, or ask the research agent what this filing means.